OrthoPediatrics Q2 Revenue Beats, Raises 2026 Guidance on Trauma Strength
KIDS sits 45% above its 52-week low of $14.42.
Summary
OrthoPediatrics delivered a clean Q2 beat: revenue of $70.5M topped the $68.25M consensus, and adjusted EBITDA of $6.8M edged past the $6.66M estimate. The 15% year-over-year revenue growth was driven by global Trauma & Deformity and OPSB product sales, with international procedure volumes also contributing. Management raised full-year 2026 revenue guidance to $265M–$269M from $263M–$267M and set adjusted EBITDA guidance at ~$25M with breakeven free cash flow — a signal of improving operating leverage. The scoliosis segment was a soft spot, with lower 7D Technology sales and fewer international set sales, partially offset by Response fusion and Verteglide. This follows a Q1 that showed 13% revenue growth and a new $20M term loan facility; the raised outlook suggests momentum is accelerating. With the stock at $20.88 and a median analyst target of $24, the beat and guidance raise could drive upward revisions and price action.
At the time of this announcement, KIDS was trading at $20.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $536.3M. The 52-week trading range was $14.42 to $22.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.